Novo Nordisk Valuation
| NOVO-B Stock | DKK 878.70 12.60 1.41% |
At this time, the firm appears to be undervalued. Novo Nordisk AS secures a last-minute Real Value of kr1003.6 per share. The latest price of the firm is kr878.7. Our model forecasts the value of Novo Nordisk AS from analyzing the firm fundamentals such as Profit Margin of 0.31 %, current valuation of 2.1 T, and Return On Equity of 0.72 as well as examining its technical indicators and probability of bankruptcy. In general, most investors recommend taking in undervalued stocks and trading overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
Undervalued
Today
Please note that Novo Nordisk's price fluctuation is very steady at this time. Calculation of the real value of Novo Nordisk AS is based on 3 months time horizon. Increasing Novo Nordisk's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Novo Nordisk AS is useful when determining the fair value of the Novo stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Novo Nordisk. Since Novo Nordisk is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Novo Stock. However, Novo Nordisk's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 878.7 | Real 1003.6 | Hype 878.7 | Naive 913.83 |
The real value of Novo Stock, also known as its intrinsic value, is the underlying worth of Novo Nordisk AS Company, which is reflected in its stock price. It is based on Novo Nordisk's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Novo Nordisk's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Novo Nordisk's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Novo Nordisk AS helps investors to forecast how Novo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Novo Nordisk more accurately as focusing exclusively on Novo Nordisk's fundamentals will not take into account other important factors: Novo Nordisk Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Novo Nordisk's current stock value. Our valuation model uses many indicators to compare Novo Nordisk value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novo Nordisk competition to find correlations between indicators driving Novo Nordisk's intrinsic value. More Info.Novo Nordisk AS is considered to be number one stock in price to earning category among related companies. It is considered to be number one stock in price to book category among related companies fabricating about 0.73 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Novo Nordisk AS is roughly 1.36 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Novo Nordisk by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Novo Nordisk's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Novo Nordisk's earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Novo Nordisk's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Novo Nordisk and how it compares across the competition.
About Novo Nordisk Valuation
The stock valuation mechanism determines the current worth of Novo Nordisk AS on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Novo Nordisk AS. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Novo Nordisk AS based exclusively on its fundamental and basic technical indicators. By analyzing Novo Nordisk's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Novo Nordisk's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Novo Nordisk. We calculate exposure to Novo Nordisk's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Novo Nordisk's related companies.Novo Nordisk AS, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Novo Nordisk operates under Pharmaceuticals And Biosciences classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 45971 people.
8 Steps to conduct Novo Nordisk's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Novo Nordisk's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Novo Nordisk's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Novo Nordisk's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Novo Nordisk's revenue streams: Identify Novo Nordisk's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Novo Nordisk's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Novo Nordisk's growth potential: Evaluate Novo Nordisk's management, business model, and growth potential.
- Determine Novo Nordisk's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Novo Nordisk's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Novo Stock analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Stocks Directory Find actively traded stocks across global markets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |